1 Organization, W. H. Global hepatitis report 2017. (World Health Organization, 2017).
2 hepatology, E. A. F. T. S. O. T. L. J. J. o. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. 67, 370-398 (2017).
3 Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. & Bell, B. P. J. J. o. h. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. 45, 529-538 (2006).
4 Chen, C. J., Yang, H. I. J. J. o. g. & hepatology. Natural history of chronic hepatitis B REVEALed. 26, 628-638 (2011).
5 Edmunds, W., Medley, G., Nokes, D., Hall, A. & Whittle, H. J. P. o. t. R. S. o. L. S. B. B. S. The influence of age on the development of the hepatitis B carrier state. 253, 197-201 (1993).
6 Suhail, M. et al. Potential mechanisms of hepatitis B virus induced liver injury. 20, 12462 (2014).
7 Ganem, D. & Prince, A. M. J. N. E. J. o. M. Hepatitis B virus infection—natural history and clinical consequences. 350, 1118-1129 (2004).
8 Fattovich, G., Stroffolini, T., Zagni, I. & Donato, F. J. G. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. 127, S35-S50 (2004).
9 Luedde, T., Schwabe, R. F. J. N. r. G. & hepatology. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. 8, 108-118 (2011).
10 Chen, W. et al. Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case–control study. 24, 386-392 (2015).
11 Aleksandrova, K. et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. 60, 858-871 (2014).
12 Ohishi, W. et al. Serum interleukin‐6 associated with hepatocellular carcinoma risk: A nested case–control study. 134, 154-163 (2014).
13 Adachi, Y. et al. Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study. 37, 15125-15132 (2016).
14 Major, J. et al. Insulin-like growth factors and liver cancer risk in male smokers. 103, 1089-1092 (2010).
15 Chen, V. L. et al. Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers. 7, 1-9 (2017).
16 Chen, C. J. & Yang, H. I. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 26, 628-638, doi:10.1111/j.1440-1746.2011.06695.x (2011).
17 Koshiol, J. et al. (Submitted).
18 Molinaro, A. M., Simon, R. & Pfeiffer, R. M. Prediction error estimation: a comparison of resampling methods. Bioinformatics 21, 3301-3307, doi:10.1093/bioinformatics/bti499 (2005).
19 Costantini, S. et al. Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. 29, 2163-2168 (2013).
20 Costantini, S. et al. Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. European cytokine network 21, 251-256, doi:10.1684/ecn.2010.0214 (2010).
21 Xie, Q. et al. Overexpression of HGF promotes HBV-induced hepatocellular carcinoma progression and is an effective indicator for Met-targeting therapy. 4, 247-260 (2013).
22 Matsumoto, K. et al. Serial changes of serum growth factor levels and liver regeneration after partial hepatectomy in healthy humans. 14, 20877-20889 (2013).
23 Stutchfield, B. M. et al. CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. 149, 1896-1909. e1814 (2015).
24 Andreasen, P. A., Kjøller, L., Christensen, L. & Duffy, M. J. J. I. j. o. c. The urokinase‐type plasminogen activator system in cancer metastasis: a review. 72, 1-22 (1997).
25 De Petro, G. et al. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. 58, 2234-2239 (1998).
26 Chan, C.-F. et al. Evaluation of nuclear factor-κB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. 10, 4140-4149 (2004).
27 Bidgoli, S. A. & Zaverhei, M. D. J. I. J. o. C. R. Differential Expression of uPA in Chronic Hepatitis B and C, Liver Cirrhosis and Hepatocellular Carcinoma: Comparison. 3, 25-32 (2007).
28 Salgado, S. et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. 2, 545-551 (2000).
29 Iredale, J. P. J. G. A cut above the rest? MMP-8 and liver fibrosis gene therapy. 126, 1199-1201 (2004).
30 Polyak, S. J., Khabar, K. S., Rezeiq, M. & Gretch, D. R. J. J. o. v. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. 75, 6209-6211 (2001).
31 Yang, K. et al. Enhanced levels of interleukin-8 are associated with hepatitis B virus infection and resistance to interferon-alpha therapy. 15, 21286-21298 (2014).
32 Jaeschke, H. J. A. J. o. P.-G. & Physiology, L. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. 290, G1083-G1088 (2006).
33 Jaeschke, H. J. A. Neutrophil-mediated tissue injury in alcoholic hepatitis. 27, 23-27 (2002).
34 Dominguez, M. et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. 136, 1639-1650 (2009).
35 Zimmermann, H. W. et al. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. 6, e21381 (2011).
36 Larrubia, J. R., Benito-Martinez, S., Calvino, M., Sanz-de-Villalobos, E. & Parra-Cid, T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 14, 7149-7159, doi:10.3748/wjg.14.7149 (2008).
37 Zeremski, M. et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48, 1440-1450, doi:10.1002/hep.22500 (2008).
38 Apolinario, A. et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 97, 2861-2870, doi:10.1111/j.1572-0241.2002.07054.x (2002).
39 Barbara, N. P., Wrana, J. L. & Letarte, M. J. J. o. B. C. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. 274, 584-594 (1999).
40 Li, C. et al. CD105 antagonizes the inhibitory signaling of transforming growth factor βl on human vascular endothelial cells. 14, 55-64 (2000).
41 Li, C. et al. TNFα down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGFß1. (2003).
42 Yagmur, E. et al. Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. 19, 755-761 (2007).
43 Leslie, W. D., Bernstein, C. N. & Leboff, M. S. J. G. AGA technical review on osteoporosis in hepatic disorders. 125, 941-966 (2003).
44 Huisman, E. J., Trip, E. J., Siersema, P. D., van Hoek, B. & van Erpecum, K. J. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol 23, 982-989, doi:10.1097/MEG.0b013e32834aa4bb (2011).
45 Goral, V., Atalay, R. & Kucukoner, M. Insulin resistance in liver cirrhosis. Hepatogastroenterology 57, 309-315 (2010).
46 Moschen, A. R. et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. 43, 973-983 (2005).
47 López-Larramona, G., Lucendo, A. J., González-Castillo, S. & Tenias, J. M. J. W. j. o. h. Hepatic osteodystrophy: an important matter for consideration in chronic liver disease. 3, 300 (2011).
48 Nedic, O., Nikolic, J. A., Prisic, S., Acimovic, J. & hajdukovic-Dragojlovic, L. Reactivity of IGF binding protein-3 isoforms towards concanavalin A in healthy adults and subjects with cirrhosis. Addict Biol 8, 81-88, doi:10.1080/1355621031000069927 (2003).
49 Wu, Y. L., Ye, J., Zhang, S., Zhong, J. & Xi, R. P. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 10, 2740-2743, doi:10.3748/wjg.v10.i18.2740 (2004).